CRYOPORT, INC. Accounts Receivable, Allowance for Credit Loss, Writeoff
CRYOPORT, INC. (CYRX) reported Accounts Receivable, Allowance for Credit Loss, Writeoff of $17.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Accounts, Notes, Loans and Financing Receivable, Gross, Allowance, and Net
us-gaap:AllowanceForDoubtfulAccountsReceivableWriteOffs · last filed 2026-03-05
- CRYOPORT, INC. accounts receivable, allowance for credit loss, writeoff for fiscal 2024 was $17.00K, a 82.11% decline from fiscal 2023.
- CRYOPORT, INC. accounts receivable, allowance for credit loss, writeoff for fiscal 2023 was $95.00K, a 111.11% increase from fiscal 2022.
- CRYOPORT, INC. accounts receivable, allowance for credit loss, writeoff for fiscal 2022 was $45.00K.
| Period end | Accounts Receivable, Allowance for Credit Loss, Writeoff 12 month | Accounts Receivable, Allowance for Credit Loss, Writeoff 12 month as first filed |
|---|---|---|
| 2024-12-31 | $17.00K 10-K · filed 2026-03-05 | $186.00K 10-K · filed 2025-03-07 |
| 2023-12-31 | $95.00K 10-K · filed 2025-03-07 | |
| 2022-12-31 | $45.00K 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |